Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Haemopoietic growth factors.

D Metcalf1

  • 1Walter and Eliza Hall Institute of Medical Research, Royal Melbourne Hospital, Parkville, Vic.

The Medical Journal of Australia
|May 16, 1988
PubMed
Summary
This summary is machine-generated.

Recombinant haemopoietic growth factors like erythropoietin are revolutionizing blood disorder and infection treatment. Future advancements promise significant clinical progress in hematology.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The SOCS box of suppressor of cytokine signaling-1 is important for inhibition of cytokine action in vivo.

Proceedings of the National Academy of Sciences of the United States of America·2001
Same author

Production of colony-stimulating factors and IL-5 by organs from three types of mice with inflammatory disease due to loss of the suppressor of cytokine signaling-1.

Journal of immunology (Baltimore, Md. : 1950)·2001
Same author

Neutralization of interferon-gamma in neonatal SOCS1-/- mice prevents fatty degeneration of the liver but not subsequent fatal inflammatory disease.

Immunology·2001
Same author

Functional analysis of Asb-1 using genetic modification in mice.

Molecular and cellular biology·2001
Same author

The multi-organ origin of interleukin-5 in the mouse.

Leukemia·2001
Same author

Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3.

Proceedings of the National Academy of Sciences of the United States of America·2001

Area of Science:

  • Biotechnology
  • Hematology
  • Immunology

Background:

  • Erythropoietin, GM-colony-stimulating factor, and G-colony-stimulating factor are established recombinant haemopoietic growth factors.
  • Numerous novel haemopoietic regulators have been identified, cloned, and are in production for clinical applications.

Purpose of the Study:

  • To highlight the clinical impact of recombinant haemopoietic growth factors.
  • To forecast future advancements in treating hematological diseases and infections.

Main Methods:

  • Review of current clinical applications of haemopoietic growth factors.
  • Analysis of emerging haemopoietic regulators undergoing development.

Main Results:

  • The first generation of recombinant haemopoietic growth factors has achieved clinical success.

Related Experiment Videos

  • A pipeline of new haemopoietic regulators is advancing towards clinical use.

    • Conclusions:

    • The next decade is poised for significant breakthroughs in managing hematological disorders and infections.
    • These advances are expected to parallel the impact of treatments for pernicious anaemia.